Inside the Industry’s Inaugural Biomarker Operations & Biospecimen Management Meeting
Introducing the inaugural Biomarker Operations & Biospecimen Management Summit, two days of practical content built entirely around the people who keep clinical trials running on the ground, not the lab bench.
From the first site collection to long-term biobanking, you will hear directly from the biomarker operations, biospecimen management, and precision medicine leaders at AstraZeneca, Regeneron, Moderna, BioNTech, and Bristol Myers Squibb. Alongside this, participate in interactive roundtables hosted by senior members of the Biospecimen Management Consortium (BMC) to tackle live industry priorities including, kit wastage and lab manual standardization.
Seize the opportunity to walk away with best-in-class strategies for consent management, sample tracking technology, AI-driven automation, and biobanking, plus direct connections with 80+ fellow decision-makers, so that you can leave your mark on the future direction of this ever-evolving field.
What Sets This Meeting Apart
An Industry First
This event has been crafted specifically to focus on biomarker operations and biospecimen management, rather than existing as an adjacent side panel bolted onto a larger meeting
Live Problem-Solving, Not Panel Talk
Tackle kit wastage and lab manual standardization head-on with the Biospecimen Management Consortium (BMC) to turn shared frustrations into industry-ready recommendations
Senior Decision Makers, Zero Gatekeepers
Boasting an audience consisting of 68% C-Level, VP, or Director-level experts from the biopharma, lab and diagnostics organizations, meet with the stakeholders actually making the decisions informing the future
Full Sample Lifecycle
Gain real-time perspectives from the start of sample lifecycle to the finish, with sessions spanning kit design, site collection, consent, tracking, AI automation, and long-term biobanking
Built by Those Actively Doing This Work
Developed alongside senior representatives at AstraZeneca, Regeneron, Moderna, BioNTech, Bristol Myers Squibb and the National Cancer Institute, the agenda seeks to solve the real problems facing this field, rather than theoretical ones
Divide & Conquer
A single sample crosses more hands, more systems, and more borders than most organizations realize, and at every one of those hand-offs, something can go wrong. This agenda follows that exact journey. Split your team across the seven stages where the risk actually lives.
1. Sample Collection Strategy
It starts at the source.
Jaime L. Fensterl, Sarepta Therapeutics, and Lokesh Agrawal, National Cancer Institute, will open the summit with a discussion on standardizing collection and pre-analytical quality, the foundation everything downstream depends on.
2. Site Management
Standardization means little, if sites cannot execute it consistently.
Amy Ripston, Biomarker Management Consortium (BMC), and Karina Bienfait, Bristol Myers Squibb, will then lead an interactive roundtable on ecosystem-wide collaboration, before Mine Cicek, Mayo Clinic, tackles the deceptively simple problem of harmonizing lab manuals across trial sites.
3. Operational Model & Central Lab Management
Once samples are moving, someone has to own the model that keeps them moving well.
Anupama Ravi, Revolution Medicines, and Jonathan Hicks, GSK, will address building a data-driven, globally scalable operating model. Followed by Michel Tarabocchia, Regeneron, closing the day on near real-time visibility and operational intelligence.
4. Sample Tracking
Visibility is nothing without the technology to act on it.
Maria V. Gujral, Bristol Myers Squibb, opens the build vs. buy conversation, continued in a panel hosted by Narasimha Rao Marella, Eli Lilly, Jonathan Saunders, Moderna, and Medha Kamat, Johnson & Johnson. Before Eduardo Almaraz, Regeneron, makes the case for proactive tracking over reactive reconciliation.
5. Consent & Regulatory Hurdles
No sample can move without permission, and that permission is getting harder to track.
Nicole Couture, Arcus Medicine, Cristin Palumbo Freeman, Bristol Myers Squibb, and Bethany Brunton, Johnson & Johnson, will walk you through consent tracking, patient withdrawals, and IVDR compliance across borders.
6. Data Reconciliation
The sample's journey and its data trail should tell the same story, however, they rarely do.
Jessica Dwyer, Candel Therapeutics, leads the conversation on linking sample results with clinical metadata, alongside a roundtable dedicated to breaking down the data silos standing in the way.
7. Biobanking
The final destination, and the one too often treated as an afterthought.
Michelle Hoarty, Dyne Therapeutics, and Kristina McGuire, Regeneron, will conclude the summit on long-term storage strategies and coordinating compliant biobanks across regions.
Delve into the Full Program to Discover
- Perspectives from 22+ Expert Speakers from Leading Pharma, Biotech & Consortia Organizations
- Real-World Insights from 20+ Case Studies Spanning the Full Sample Lifecycle
- Dedicated Networking Opportunities Built to Strengthen & Spark Collaborations
- The Complete Session, Panel & Roundtable Details Hyper-Relevant to Every Stakeholder
- The Industry's First & Only Dedicated Forum to the Biomarker Operations & Biospecimen Management Community
Attending Companies Include
Discover the New Agenda
Hear the latest breakthroughs in biomarker operations and gain exclusive insights across industry-led sessions, interactive BMC roundtables, and discussion-based panels
Partner With the Future
Position your organization directly alongside the architects of modern biomarker operations to ensure your brand is at the heart of every sample lifecycle decision
Join Biomarker Stakeholders
Be part of the first forum dedicated to this space, connecting with senior decision-makers from biopharma, central labs, and diagnostics across two action-packed conference days